MXPA03011522A - Derivados de naftil indol sustiduidos como inhibidores del tipo 1 del inhibidor del activador del plasmingeno. - Google Patents

Derivados de naftil indol sustiduidos como inhibidores del tipo 1 del inhibidor del activador del plasmingeno.

Info

Publication number
MXPA03011522A
MXPA03011522A MXPA03011522A MXPA03011522A MXPA03011522A MX PA03011522 A MXPA03011522 A MX PA03011522A MX PA03011522 A MXPA03011522 A MX PA03011522A MX PA03011522 A MXPA03011522 A MX PA03011522A MX PA03011522 A MXPA03011522 A MX PA03011522A
Authority
MX
Mexico
Prior art keywords
optionally substituted
alkyl
pai
alkanoyl
inhibitors
Prior art date
Application number
MXPA03011522A
Other languages
English (en)
Inventor
Christian Mayer Scott
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MXPA03011522A publication Critical patent/MXPA03011522A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Child & Adolescent Psychology (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)

Abstract

La presente invencion proporciona compuestos inhibidores de PAI-1 de la Formula (I): (ver formula): en donde: R1, R2, R3, y R4 son cada uno H, alquilo, alcanoilo, halo, OH, arilo opcionalmente substituido con R8, perfluoroalquilo, alcoxi, amino, alquilamino, dialquilamino, perfluoroalcoxi; R5 es H, alquilo, perfluoroalquilo, arilo opcionalmente substituido con R8, alcanoilo, aroilo opcionalmente substituido con R8, R6 es H, alquilo, alquilarilo, bencilo opcionalmente substituido con R8, alcanoilo, aroilo opcionalmente substituido con R8; R7 es H, alquilo, alquilarilo, arilo opcionalmente substituido con R8; n es 0-6; A es COOH, o una substancia imitadora acida tal como tetrazol, S03H, P03H2, acido tetronico, etc.; R8 es H, alquilo, cicloalquilo, alcanoilo, halo, OH, perfluoroalquilo, alcoxi, amino, alquilamino, dialquilamino, perfluoroalcoxi; o una sal del mismo farmaceuticamente aceptable; asi como a composiciones farmaceuticas y metodos de tratamiento que utilizan estos compuestos.
MXPA03011522A 2001-06-20 2002-06-18 Derivados de naftil indol sustiduidos como inhibidores del tipo 1 del inhibidor del activador del plasmingeno. MXPA03011522A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29965101P 2001-06-20 2001-06-20
PCT/US2002/021113 WO2003000684A1 (en) 2001-06-20 2002-06-18 Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (pai-1)

Publications (1)

Publication Number Publication Date
MXPA03011522A true MXPA03011522A (es) 2004-03-19

Family

ID=23155676

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03011522A MXPA03011522A (es) 2001-06-20 2002-06-18 Derivados de naftil indol sustiduidos como inhibidores del tipo 1 del inhibidor del activador del plasmingeno.

Country Status (25)

Country Link
US (4) US6800654B2 (es)
EP (1) EP1397356B1 (es)
JP (1) JP4520144B2 (es)
KR (1) KR20040007744A (es)
CN (1) CN1280288C (es)
AR (1) AR036101A1 (es)
AT (1) ATE431346T1 (es)
AU (1) AU2002316533B2 (es)
BR (1) BR0210504A (es)
CA (1) CA2448798C (es)
CO (1) CO5540286A2 (es)
DE (1) DE60232328D1 (es)
EA (1) EA009696B1 (es)
EC (1) ECSP034904A (es)
ES (1) ES2325733T3 (es)
HU (1) HUP0400233A3 (es)
IL (1) IL159449A0 (es)
MX (1) MXPA03011522A (es)
NO (2) NO326316B1 (es)
NZ (1) NZ530312A (es)
PL (1) PL367525A1 (es)
TW (1) TWI224101B (es)
UA (1) UA78708C2 (es)
WO (1) WO2003000684A1 (es)
ZA (1) ZA200400380B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7291639B2 (en) * 2001-06-20 2007-11-06 Wyeth Aryloxy-acetic acid compounds useful as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
WO2003000253A1 (en) * 2001-06-20 2003-01-03 Wyeth Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
TWI224101B (en) * 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
MXPA05006287A (es) * 2002-12-10 2005-09-08 Wyeth Corp Derivados de acido indoloxo-acetilaminoacetico sustituidos como inhibidores del inhibidor del activador de plasminogeno 1 (pai-1).
CN1726190A (zh) 2002-12-10 2006-01-25 惠氏公司 作为纤溶酶原激活物抑制剂－1(pai－1)的抑制剂的取代3－羰基－1h－吲哚－1－基乙酸衍生物
UA80453C2 (en) * 2002-12-10 2007-09-25 Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
WO2004052853A2 (en) * 2002-12-10 2004-06-24 Wyeth Substituted 3-alkyl and 3-arylalkyl 1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
CA2509191A1 (en) * 2002-12-10 2004-06-24 Wyeth Aryl, aryloxy, and alkyloxy substituted 1h-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
JP4390460B2 (ja) * 2003-02-21 2009-12-24 株式会社静岡カフェイン工業所 オキサゾール誘導体
US7351726B2 (en) * 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
US7420083B2 (en) * 2003-09-25 2008-09-02 Wyeth Substituted aryloximes
US7442805B2 (en) * 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
US7342039B2 (en) * 2003-09-25 2008-03-11 Wyeth Substituted indole oximes
US7163954B2 (en) * 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
US7332521B2 (en) * 2003-09-25 2008-02-19 Wyeth Substituted indoles
US7141592B2 (en) * 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7582773B2 (en) * 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
US7265148B2 (en) * 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7268159B2 (en) * 2003-09-25 2007-09-11 Wyeth Substituted indoles
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
US7534894B2 (en) * 2003-09-25 2009-05-19 Wyeth Biphenyloxy-acids
US7446201B2 (en) * 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
US7115815B2 (en) * 2003-10-31 2006-10-03 Adc Telecommunications, Inc. Cable utilizing varying lay length mechanisms to minimize alien crosstalk
BRPI0514549A (pt) * 2004-08-23 2008-06-17 Wyeth Corp ácidos de pirrol-naftila como inibidores de pai-1
CN101044127A (zh) * 2004-08-23 2007-09-26 惠氏公司 用作纤溶酶原激活剂抑制剂－1的噻唑基－萘基酸
RU2007106868A (ru) * 2004-08-23 2008-09-27 Вайет (Us) Оксазол-нафтиловые кислоты и их применение в качестве модуляторов ингибитора активатора плазминогена-1 (pai) для лечения тромбоза и сердечно-сосудистых заболеваний
US7323483B2 (en) * 2005-01-27 2008-01-29 Wyeth Processes and compounds for the preparation of substituted naphthylindole derivatives
EP1919866A2 (en) * 2005-08-17 2008-05-14 Wyeth a Corporation of the State of Delaware Substituted indoles and use thereof
CN101384256A (zh) * 2006-02-27 2009-03-11 惠氏公司 用于治疗肌肉病状的pai-1抑制剂
EP2080751A4 (en) 2006-10-12 2011-06-22 Inst Med Molecular Design Inc CARBOXYLIC ACID DERIVATIVE
EP2072498A4 (en) * 2006-10-12 2012-07-18 Inst Med Molecular Design Inc N-PHENYLOXAMIDE ACID DERIVATIVE
US8759327B2 (en) 2007-04-16 2014-06-24 The Regents Of The University Of Michigan Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism
US9120744B2 (en) * 2007-04-16 2015-09-01 The Regents Of The University Of Michigan Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism
JP5213855B2 (ja) 2007-06-27 2013-06-19 興和株式会社 ピラゾロン誘導体
CA2703494A1 (en) 2007-10-23 2009-04-30 Institute Of Medicinal Molecular Design, Inc. Inhibitor of pai-1 production
AU2009234899A1 (en) 2008-04-11 2009-10-15 Institute Of Medicinal Molecular Design, Inc. PAI-1 inhibitor
US8633245B2 (en) * 2008-04-11 2014-01-21 Institute Of Medicinal Molecular Design, Inc. PAI-1 inhibitor
CN105008323B (zh) 2012-10-31 2018-11-06 密歇根大学董事会 纤溶酶原激活物抑制因子-1抑制剂和其使用方法
EP3395354B1 (en) 2015-12-18 2024-05-22 Talengen International Limited Plasminogen for use in treating diabetic nephropathy
CN106890324A (zh) * 2015-12-18 2017-06-27 深圳瑞健生命科学研究院有限公司 一种预防和治疗糖尿病肾病的方法
EP3556384B1 (en) 2016-12-15 2024-04-10 Talengen International Limited Plasminogen for use in treating diabetes
EP3657946A4 (en) 2017-07-27 2021-04-07 The Regents of The University of Michigan PLASMINOGEN ACTIVATOR INHIBITOR 1 (PAI-1) INHIBITOR AND METHOD OF APPLICATION
CN114057623B (zh) * 2021-12-07 2023-07-21 湖南第一师范学院 一种n-萘基吲哚衍生物及其合成方法

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3026325A (en) * 1959-01-26 1962-03-20 Upjohn Co 5-hydroxy-alpha-alkyltryptophans
US3476770A (en) * 1967-04-14 1969-11-04 Parke Davis & Co 2-methyl-7-phenylindole-3-acetic acid compounds
GB1321433A (en) 1968-01-11 1973-06-27 Roussel Uclaf 1,2,3,6-tetrasubstituted indoles
US3557142A (en) * 1968-02-20 1971-01-19 Sterling Drug Inc 4,5,6,7-tetrahydro-indole-lower-alkanoic acids and esters
FR2244499A1 (en) 1973-06-07 1975-04-18 Delalande Sa Indol-3-ylformaldoxime carbamates - for treating anxiety epilepsy, cardiac arrhythmias, asthma, intestinal spasm, peptic ulcer, cardiac insufficiency
US4519909A (en) * 1977-07-11 1985-05-28 Akzona Incorporated Microporous products
DE3147276A1 (de) 1981-11-28 1983-06-09 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung von indolderivaten, deren verwendung als wertvolle zwischenprodukte und neue 4-hydroxyindole
FR2525474A1 (fr) * 1982-04-26 1983-10-28 Roussel Uclaf Nouvelle forme pharmaceutique orale de clometacine
DE3531658A1 (de) * 1985-09-05 1987-03-12 Boehringer Mannheim Gmbh Heterocyclisch substituierte indole, zwischenprodukte, verfahren zu ihrer herstellung und arzneimittel
US4859538A (en) * 1986-11-20 1989-08-22 Ribi Hans O Novel lipid-protein compositions and articles and methods for their preparation
US5164372A (en) * 1989-04-28 1992-11-17 Fujisawa Pharmaceutical Company, Ltd. Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same
PH30133A (en) * 1989-09-07 1997-01-21 Abbott Lab Indole-, benzofuran-, and benzothiophene-containing lipoxygenase inhibiting compounds
US5420289A (en) * 1989-10-27 1995-05-30 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
DE4035961A1 (de) * 1990-11-02 1992-05-07 Thomae Gmbh Dr K Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5151435A (en) 1991-04-08 1992-09-29 Merck & Co., Inc. Angiotensin ii antagonists incorporating an indole or dihydroindole
IL101785A0 (en) 1991-05-10 1992-12-30 Fujisawa Pharmaceutical Co Urea derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
GB9123396D0 (en) 1991-11-04 1991-12-18 Hoffmann La Roche A process for the manufacture of substituted maleimides
US5502187A (en) * 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
US5612360A (en) * 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
DE4242675A1 (de) 1992-12-17 1994-06-23 Basf Ag Neue Hydroxyiminoalkylindolcarbonsäure-Derivate, ihre Herstellung und Verwendung
ZA939516B (en) 1992-12-22 1994-06-06 Smithkline Beecham Corp Endothelin receptor antagonists
IL109568A0 (en) 1993-05-19 1994-08-26 Fujisawa Pharmaceutical Co Urea derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
US6756388B1 (en) 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
DE4338770A1 (de) 1993-11-12 1995-05-18 Matthias Dr Lehr Indol-2-alkansäuren und ihre Derivate als Hemmstoffe der Phospholipase A¶2¶
CA2134192A1 (en) 1993-11-12 1995-05-13 Michael L. Denney 5, 6-bicyclic glycoprotein iib/iiia antagonists
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5482960A (en) * 1994-11-14 1996-01-09 Warner-Lambert Company Nonpeptide endothelin antagonists
US5552412A (en) 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
IL117208A0 (en) 1995-02-23 1996-06-18 Nissan Chemical Ind Ltd Indole type thiazolidines
KR100430059B1 (ko) 1995-04-10 2004-09-24 후지사와 야꾸힝 고교 가부시키가이샤 cGMP-PDE억제제로서의인돌유도체
US5728724A (en) 1995-08-17 1998-03-17 Eli Lilly And Company Benzothiophene compounds
IL120724A0 (en) 1995-09-01 1997-08-14 Lilly Co Eli Indolyl neuropeptide Y receptor antagonists
DE19543639A1 (de) 1995-11-23 1997-05-28 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
GB9609641D0 (en) 1996-05-09 1996-07-10 Pfizer Ltd Compounds useful in therapy
EP2223920A3 (en) * 1996-06-19 2011-09-28 Aventis Pharma Limited Substituted azabicyclic compounds
CA2207083A1 (en) 1996-07-15 1998-01-15 Brian William Grinnell Benzothiophene compounds, and uses and formulations thereof
CA2207141A1 (en) * 1996-07-15 1998-01-15 David Thompson Berg Benzothiophene compounds, and uses and formulations thereof
EP0822185A1 (en) 1996-07-31 1998-02-04 Pfizer Inc. B-3-adrenergic agonists as antidiabetic and antiobesity agents
AU717430B2 (en) 1996-08-26 2000-03-23 Genetics Institute, Llc Inhibitors of phospholipase enzymes
DE19753522A1 (de) 1997-12-03 1999-06-10 Boehringer Ingelheim Pharma Substituierte Indole, ihre Herstellung und ihre Verwendung als Arzneimittel
CN1310706A (zh) 1998-02-25 2001-08-29 遗传研究所有限公司 磷脂酶抑制剂
ID26123A (id) 1998-02-25 2000-11-23 Genetics Inst Penghambat-penghambat phospholipase a2
JP2002504539A (ja) 1998-02-25 2002-02-12 ジェネティックス・インスチチュート・インコーポレーテッド ホスホリパーゼ酵素の阻害剤
SE9800836D0 (sv) 1998-03-13 1998-03-13 Astra Ab New Compounds
ATE269861T1 (de) 1998-03-31 2004-07-15 Inst For Pharm Discovery Inc Substituierte indolalkansäure
FR2777886B1 (fr) * 1998-04-27 2002-05-31 Adir Nouveaux derives benzothiopheniques, benzofuraniques et indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6110963A (en) * 1998-05-12 2000-08-29 American Home Products Corporation Aryl-oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
CA2331120A1 (en) 1998-05-12 1999-11-18 Iwan Gunawan Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
EA200001175A1 (ru) 1998-05-12 2001-06-25 Американ Хоум Продактс Корпорейшн Бензотиофены, бензофураны и индолы, полезные в лечении устойчивости к инсулину и гипергликемии
US6166069A (en) * 1998-05-12 2000-12-26 American Home Products Corporation Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
US6232322B1 (en) * 1998-05-12 2001-05-15 American Home Products Corporation Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
US6251936B1 (en) * 1998-05-12 2001-06-26 American Home Products Corporation Benzothiophenes, benzofurans, and indoles useful in the treatment of insulin resistance and hyperglycemia
AU4058399A (en) * 1998-11-20 2000-06-13 Torii Pharmaceutical Co., Ltd. Naphthalene derivatives
TNSN99224A1 (fr) 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
CA2353151A1 (en) * 1998-12-16 2000-06-22 Boehringer Ingelheim Pharma Kg Substituted aryl and heteroaryl derivatives, the preparation thereof and their use as medicaments
GB9827882D0 (en) 1998-12-17 1999-02-10 Smithkline Beecham Plc Novel compounds
AU2319100A (en) 1999-01-28 2000-08-18 Nippon Shinyaku Co. Ltd. Amide derivatives and drug compositions
GB9902453D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902459D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
AU782404B2 (en) 1999-04-28 2005-07-28 Sanofi-Aventis Deutschland Gmbh Tri-aryl acid derivatives as PPAR receptor ligands
JP4598278B2 (ja) 1999-04-28 2010-12-15 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｐｐａｒ受容体リガンドとしてのジアリール酸誘導体
GB9919411D0 (en) 1999-08-18 1999-10-20 Zeneca Ltd Chemical compounds
GB9919413D0 (en) * 1999-08-18 1999-10-20 Zeneca Ltd Chemical compounds
FR2799756B1 (fr) 1999-10-15 2001-12-14 Adir Nouveaux derives benzothiopheniques, benzofuraniques et indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE19963178A1 (de) * 1999-12-27 2001-07-05 Gruenenthal Gmbh Substituierte Indol-Mannichbasen
DE10031281A1 (de) * 2000-06-27 2002-01-10 Creavis Tech & Innovation Gmbh Polyelektrolytbeschichteter, stoffdurchlässiger Verbundwerkstoff, Verfahren zu dessen Herstellung und die Verwendung des Verbundwerkstoffes
EP1341761A1 (en) 2000-10-10 2003-09-10 Smithkline Beecham Corporation SUBSTITUTED INDOLES, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH INDOLES AND THEIR USE AS PPAR-$g(g) BINDING AGENTS
US6951848B2 (en) 2001-03-12 2005-10-04 Millennium Pharmaceuticals, Inc., Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
US6808908B2 (en) * 2001-05-30 2004-10-26 Porex Technologies Corporation Functionalized porous substrate for binding chemical and biological moieties
FR2825706B1 (fr) * 2001-06-06 2003-12-12 Pf Medicament Nouveaux derives de benzothienyle ou d'indole, leur preparation et leur utilisation comme inhibiteurs de proteines prenyl transferase
WO2003000253A1 (en) 2001-06-20 2003-01-03 Wyeth Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
TWI224101B (en) * 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
US7291639B2 (en) * 2001-06-20 2007-11-06 Wyeth Aryloxy-acetic acid compounds useful as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
TWI240723B (en) * 2001-06-20 2005-10-01 Wyeth Corp Substituted naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7456025B2 (en) * 2001-08-28 2008-11-25 Porex Corporation Sintered polymer membrane for analyte detection device
KR100810468B1 (ko) * 2001-10-10 2008-03-07 씨제이제일제당 (주) 사이클로옥시게나제-2의 저해제로서 선택성이 뛰어난1ｈ-인돌 유도체
CN1642910A (zh) 2002-02-12 2005-07-20 威斯康星校友研究基金会 用于ah受体作为配体的吲哚噻唑化合物的合成
UA80453C2 (en) * 2002-12-10 2007-09-25 Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
CA2509191A1 (en) * 2002-12-10 2004-06-24 Wyeth Aryl, aryloxy, and alkyloxy substituted 1h-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
MXPA05006287A (es) * 2002-12-10 2005-09-08 Wyeth Corp Derivados de acido indoloxo-acetilaminoacetico sustituidos como inhibidores del inhibidor del activador de plasminogeno 1 (pai-1).
WO2004052853A2 (en) * 2002-12-10 2004-06-24 Wyeth Substituted 3-alkyl and 3-arylalkyl 1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
CN1726190A (zh) * 2002-12-10 2006-01-25 惠氏公司 作为纤溶酶原激活物抑制剂－1(pai－1)的抑制剂的取代3－羰基－1h－吲哚－1－基乙酸衍生物
US7442805B2 (en) * 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
US7332521B2 (en) * 2003-09-25 2008-02-19 Wyeth Substituted indoles
US7582773B2 (en) * 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
US7351726B2 (en) * 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
US20050215626A1 (en) * 2003-09-25 2005-09-29 Wyeth Substituted benzofuran oximes
US7163954B2 (en) * 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
US7342039B2 (en) * 2003-09-25 2008-03-11 Wyeth Substituted indole oximes
US7141592B2 (en) * 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7420083B2 (en) * 2003-09-25 2008-09-02 Wyeth Substituted aryloximes
US7265148B2 (en) * 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7268159B2 (en) * 2003-09-25 2007-09-11 Wyeth Substituted indoles
US7446201B2 (en) * 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids

Also Published As

Publication number Publication date
US7629377B2 (en) 2009-12-08
ATE431346T1 (de) 2009-05-15
PL367525A1 (en) 2005-02-21
EA200400054A1 (ru) 2004-04-29
JP2004534825A (ja) 2004-11-18
EP1397356B1 (en) 2009-05-13
WO2003000684A1 (en) 2003-01-03
CO5540286A2 (es) 2005-07-29
US20040266733A1 (en) 2004-12-30
CA2448798C (en) 2010-07-20
CN1280288C (zh) 2006-10-18
ES2325733T3 (es) 2009-09-15
US6939886B2 (en) 2005-09-06
EA009696B1 (ru) 2008-02-28
JP4520144B2 (ja) 2010-08-04
US7351730B2 (en) 2008-04-01
US20060014725A1 (en) 2006-01-19
NO20035635D0 (no) 2003-12-17
HUP0400233A3 (en) 2008-10-28
NO20084390L (no) 2003-12-17
DE60232328D1 (de) 2009-06-25
KR20040007744A (ko) 2004-01-24
ZA200400380B (en) 2006-06-28
UA78708C2 (en) 2007-04-25
ECSP034904A (es) 2004-01-28
AR036101A1 (es) 2004-08-11
US20030032626A1 (en) 2003-02-13
EP1397356A1 (en) 2004-03-17
CA2448798A1 (en) 2003-01-03
CN1549814A (zh) 2004-11-24
NO326316B1 (no) 2008-11-10
US20080182883A1 (en) 2008-07-31
NZ530312A (en) 2005-05-27
IL159449A0 (en) 2004-06-01
US6800654B2 (en) 2004-10-05
TWI224101B (en) 2004-11-21
AU2002316533B2 (en) 2007-10-18
HUP0400233A2 (hu) 2004-08-30
BR0210504A (pt) 2004-05-18

Similar Documents

Publication Publication Date Title
MXPA03011522A (es) Derivados de naftil indol sustiduidos como inhibidores del tipo 1 del inhibidor del activador del plasmingeno.
EA200400073A1 (ru) Пирролопиримидины как ингибиторы протеинкиназы
DE60226469D1 (de) Biphenylkarbonsäureamidderivate als p38 kinase-inhibitoren
ATE307119T1 (de) Bicyclische protein-farnesyl-transferase inhibitoren
TNSN01018A1 (en) Treatment of neurodegenerative disease
IL165262A (en) Kinase inhibitors and pharmaceutical compositions containing them
ATE159950T1 (de) N-alkyl-2-substituierte atp-analoge
EP1248612A4 (en) NEW SUBSTANCES AND COMPOUNDS AS PROTEASE INHIBITORS
GB9801690D0 (en) Therapeutic agents
IN2005KO00312A (es)
TR200400541T4 (tr) Terapide faydalı tropan türevleri.
AP2003002929A0 (en) Pyrrolopyrimidines as protein kinase inhibitors
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
FI950309A0 (fi) Proliiniamidijohdannaisia
HUP0301336A2 (hu) Réztartalmú amin-oxidázok inhibitorai és alkalmazásuk gyógyszerkészítmények előállítására
YU41600A (sh) 2,3-substituisana indol jedinjenja kao cox-2 inhibitori
MY123908A (en) Meta-azacyclic amino benzoic acid compounds and derivatives thereof
DE69722858D1 (de) Intimale verdickungsinhibitoren
EA200300982A1 (ru) Гетероциклические производные для лечения рака и других пролиферативных заболеваний
MY131193A (en) 7-(2-aminoethyl)-benzothiazolones
EA200100090A3 (ru) Новые пиперидин-4-сульфонамидные производные, способ их получения и содержащие их фармацевтические композиции
DK0902684T3 (da) Hexahydro-pyrido (4,3-B) indolderivater som antipsykotiske lægemidler
EA200101230A1 (ru) Новые ингибиторы металлопротеаз, метод их получения и содержащие их фармацевтические композиции
MXPA03004023A (es) Compuestos quimicos.
HUP0203118A2 (hu) Béta-diszubsztituált metalloproteáz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk

Legal Events

Date Code Title Description
FG Grant or registration